{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:04:00Z","timestamp":1788919440458,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T00:00:00Z","timestamp":1506643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T00:00:00Z","timestamp":1506643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/bcj.2017.96","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T17:28:58Z","timestamp":1506706138000},"page":"e614-e614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy"],"prefix":"10.1038","volume":"7","author":[{"given":"Y","family":"Kusano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Terui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Tsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Hatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,29]]},"reference":[{"key":"BFbcj201796_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2010","unstructured":"Salles G, Seymour JF, Offner F, Belada D, Xerri L, Feugier P et al. Rituximab maintenance for 6 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2010; 377: 42\u201351.","journal-title":"Lancet"},{"key":"BFbcj201796_CR2","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"M Ghielmini","year":"2004","unstructured":"Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly 4 schedule. Blood 2004; 103: 4416\u20134423.","journal-title":"Blood"},{"key":"BFbcj201796_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1126\/science.1631559","volume":"257","author":"T Takeshita","year":"1992","unstructured":"Takeshita T, Asao H, Ohtani K, Ishii N, Kumaki S, Tanaka N et al. Cloning of the gamma chain of the human IL-2 receptor. Science 1992; 257: 379\u2013382.","journal-title":"Science"},{"key":"BFbcj201796_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3109\/10428190009057638","volume":"37","author":"N Kono","year":"2000","unstructured":"Kono N, Kanda Y, Yamamoto R, Chizuka A, Suguro M, Hamaki T et al. Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin\u2019s lymphoma: a single center study in Japan. Leuk Lymphoma 2000; 37: 151\u2013156.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201796_CR5","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/annonc\/mdn677","volume":"20","author":"D Ennishi","year":"2009","unstructured":"Ennishi D, Yokoyama M, Terui Y, Asai H, Sakajiri S, Mishima Y et al. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Ann Oncol 2009; 20: 526\u2013533.","journal-title":"Ann Oncol"},{"key":"BFbcj201796_CR6","doi-asserted-by":"publisher","first-page":"12589","DOI":"10.1007\/s13277-016-5124-9","volume":"37","author":"L He","year":"2016","unstructured":"He L, Liang JH, Wu JZ, Li Y, Qin SC, Miao Y et al. Low absolute CD4+ T cell counts in peripheral blood are associated with inferior survival in follicular lymphoma. Tumor Biol 2016; 37: 12589\u201312595.","journal-title":"Tumor Biol"},{"key":"BFbcj201796_CR7","doi-asserted-by":"publisher","first-page":"e558","DOI":"10.1038\/bcj.2017.37","volume":"7","author":"Y Kusano","year":"2017","unstructured":"Kusano Y, Yokoyama M, Terui Y, Nishimura N, Mishima Y, Ueda K et al. Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma. Blood Cancer J 2017; 7: e558.","journal-title":"Blood Cancer J"},{"key":"BFbcj201796_CR8","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1182\/blood-2005-08-3376","volume":"107","author":"ZZ Yang","year":"2006","unstructured":"Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM . Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006; 107: 3639\u20133646.","journal-title":"Blood"},{"key":"BFbcj201796_CR9","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ni1263","volume":"6","author":"JD Fontenot","year":"2005","unstructured":"Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY . A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6: 1142\u20131151.","journal-title":"Nat Immunol"},{"key":"BFbcj201796_CR10","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1182\/blood-2011-03-340885","volume":"118","author":"ZZ Yang","year":"2011","unstructured":"Yang ZZ, Grote DM, Ziesmer SC, Manske MK, Witzig TE, Novak AJ et al. Soluble IL-2R\u03b1 facilitates IL-2\u2013mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood 2011; 118: 2809\u20132820.","journal-title":"Blood"},{"key":"BFbcj201796_CR11","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579\u2013586.","journal-title":"J Clin Oncol"},{"key":"BFbcj201796_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large- B-cell lymphoma. N Engl J Med 2002; 346: 235\u2013242.","journal-title":"N Engl J Med"},{"key":"BFbcj201796_CR13","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1200\/jco.2007.25.18_suppl.8004","volume":"25","author":"HS Hochster","year":"2007","unstructured":"Hochster HS, Weller E, Gascoyne R, Ryan T, Habermann TM, Gordon LI et al. Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: results from the E1496 Trial. J Clin Oncol 2007; 25: 8004.","journal-title":"J Clin Oncol"},{"key":"BFbcj201796_CR14","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D et al. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123: 2944\u20132952.","journal-title":"Blood"},{"key":"BFbcj201796_CR15","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203\u20131210.","journal-title":"Lancet"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201796.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201796","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bcj.2017.96","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201796.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T17:29:12Z","timestamp":1671730152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,29]]},"references-count":15,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9]]}},"alternative-id":["BFbcj201796"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2017.96","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,29]]},"assertion":[{"value":"29 September 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors except the following four have no conflict of interest to declare:YT has reported honoraria from Janssen. MY, YM and NN have reported consultancy from Chugai. KH has reported consultancy from Meiji-Seika and Otsuka, honoraria from Kyowa Kirin and research funding from Chugai and Kyowa Kirin.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}